CN104321649A - 用于诊断阿扎胞苷耐药性的试验 - Google Patents

用于诊断阿扎胞苷耐药性的试验 Download PDF

Info

Publication number
CN104321649A
CN104321649A CN201380013105.4A CN201380013105A CN104321649A CN 104321649 A CN104321649 A CN 104321649A CN 201380013105 A CN201380013105 A CN 201380013105A CN 104321649 A CN104321649 A CN 104321649A
Authority
CN
China
Prior art keywords
bcl2l10
azacitidine
patient
biological fluid
protein
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Pending
Application number
CN201380013105.4A
Other languages
English (en)
Chinese (zh)
Inventor
托马斯·克鲁塞奥
帕特里克·奥伯格
基洛姆·罗伯特
弗雷德里克·卢西亚诺
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
National Institute Of Health And Medicine
Universite de Nice Sophia Antipolis UNSA
Centre Hospitalier Universitaire de Nice
Original Assignee
National Institute Of Health And Medicine
Universite de Nice Sophia Antipolis UNSA
Centre Hospitalier Universitaire de Nice
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by National Institute Of Health And Medicine, Universite de Nice Sophia Antipolis UNSA, Centre Hospitalier Universitaire de Nice filed Critical National Institute Of Health And Medicine
Publication of CN104321649A publication Critical patent/CN104321649A/zh
Pending legal-status Critical Current

Links

Classifications

    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N33/00—Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
    • G01N33/48—Biological material, e.g. blood, urine; Haemocytometers
    • G01N33/50—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
    • G01N33/53—Immunoassay; Biospecific binding assay; Materials therefor
    • G01N33/575—Immunoassay; Biospecific binding assay; Materials therefor for cancer
    • G01N33/57575—Immunoassay; Biospecific binding assay; Materials therefor for cancer involving oncogenic proteins
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N33/00—Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
    • G01N33/48—Biological material, e.g. blood, urine; Haemocytometers
    • G01N33/50—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
    • G01N33/5005—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving human or animal cells
    • G01N33/5008—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving human or animal cells for testing or evaluating the effect of chemical or biological compounds, e.g. drugs, cosmetics
    • G01N33/5014—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving human or animal cells for testing or evaluating the effect of chemical or biological compounds, e.g. drugs, cosmetics for testing toxicity
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12Q—MEASURING OR TESTING PROCESSES INVOLVING ENZYMES, NUCLEIC ACIDS OR MICROORGANISMS; COMPOSITIONS OR TEST PAPERS THEREFOR; PROCESSES OF PREPARING SUCH COMPOSITIONS; CONDITION-RESPONSIVE CONTROL IN MICROBIOLOGICAL OR ENZYMOLOGICAL PROCESSES
    • C12Q1/00—Measuring or testing processes involving enzymes, nucleic acids or microorganisms; Compositions therefor; Processes of preparing such compositions
    • C12Q1/68—Measuring or testing processes involving enzymes, nucleic acids or microorganisms; Compositions therefor; Processes of preparing such compositions involving nucleic acids
    • C12Q1/6876—Nucleic acid products used in the analysis of nucleic acids, e.g. primers or probes
    • C12Q1/6883—Nucleic acid products used in the analysis of nucleic acids, e.g. primers or probes for diseases caused by alterations of genetic material
    • C12Q1/6886—Nucleic acid products used in the analysis of nucleic acids, e.g. primers or probes for diseases caused by alterations of genetic material for cancer
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N33/00—Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
    • G01N33/48—Biological material, e.g. blood, urine; Haemocytometers
    • G01N33/50—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
    • G01N33/5005—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving human or animal cells
    • G01N33/5008—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving human or animal cells for testing or evaluating the effect of chemical or biological compounds, e.g. drugs, cosmetics
    • G01N33/5044—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving human or animal cells for testing or evaluating the effect of chemical or biological compounds, e.g. drugs, cosmetics involving specific cell types
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N33/00—Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
    • G01N33/48—Biological material, e.g. blood, urine; Haemocytometers
    • G01N33/50—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
    • G01N33/53—Immunoassay; Biospecific binding assay; Materials therefor
    • G01N33/575—Immunoassay; Biospecific binding assay; Materials therefor for cancer
    • G01N33/57505—Immunoassay; Biospecific binding assay; Materials therefor for cancer of the blood, e.g. leukaemia
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12Q—MEASURING OR TESTING PROCESSES INVOLVING ENZYMES, NUCLEIC ACIDS OR MICROORGANISMS; COMPOSITIONS OR TEST PAPERS THEREFOR; PROCESSES OF PREPARING SUCH COMPOSITIONS; CONDITION-RESPONSIVE CONTROL IN MICROBIOLOGICAL OR ENZYMOLOGICAL PROCESSES
    • C12Q2600/00—Oligonucleotides characterized by their use
    • C12Q2600/106—Pharmacogenomics, i.e. genetic variability in individual responses to drugs and drug metabolism
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12Q—MEASURING OR TESTING PROCESSES INVOLVING ENZYMES, NUCLEIC ACIDS OR MICROORGANISMS; COMPOSITIONS OR TEST PAPERS THEREFOR; PROCESSES OF PREPARING SUCH COMPOSITIONS; CONDITION-RESPONSIVE CONTROL IN MICROBIOLOGICAL OR ENZYMOLOGICAL PROCESSES
    • C12Q2600/00—Oligonucleotides characterized by their use
    • C12Q2600/118—Prognosis of disease development
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12Q—MEASURING OR TESTING PROCESSES INVOLVING ENZYMES, NUCLEIC ACIDS OR MICROORGANISMS; COMPOSITIONS OR TEST PAPERS THEREFOR; PROCESSES OF PREPARING SUCH COMPOSITIONS; CONDITION-RESPONSIVE CONTROL IN MICROBIOLOGICAL OR ENZYMOLOGICAL PROCESSES
    • C12Q2600/00—Oligonucleotides characterized by their use
    • C12Q2600/158—Expression markers
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N2333/00—Assays involving biological materials from specific organisms or of a specific nature
    • G01N2333/435—Assays involving biological materials from specific organisms or of a specific nature from animals; from humans
    • G01N2333/46—Assays involving biological materials from specific organisms or of a specific nature from animals; from humans from vertebrates
    • G01N2333/47—Assays involving proteins of known structure or function as defined in the subgroups
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N2333/00—Assays involving biological materials from specific organisms or of a specific nature
    • G01N2333/82—Translation products from oncogenes
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N2800/00—Detection or diagnosis of diseases
    • G01N2800/52—Predicting or monitoring the response to treatment, e.g. for selection of therapy based on assay results in personalised medicine; Prognosis
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N2800/00—Detection or diagnosis of diseases
    • G01N2800/54—Determining the risk of relapse

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Engineering & Computer Science (AREA)
  • Immunology (AREA)
  • Biomedical Technology (AREA)
  • Chemical & Material Sciences (AREA)
  • Molecular Biology (AREA)
  • Hematology (AREA)
  • Urology & Nephrology (AREA)
  • Cell Biology (AREA)
  • Pathology (AREA)
  • Analytical Chemistry (AREA)
  • Microbiology (AREA)
  • Physics & Mathematics (AREA)
  • Biotechnology (AREA)
  • Biochemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Toxicology (AREA)
  • General Physics & Mathematics (AREA)
  • Food Science & Technology (AREA)
  • Medicinal Chemistry (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Tropical Medicine & Parasitology (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Organic Chemistry (AREA)
  • Wood Science & Technology (AREA)
  • Zoology (AREA)
  • Genetics & Genomics (AREA)
  • Oncology (AREA)
  • Biophysics (AREA)
  • Hospice & Palliative Care (AREA)
  • General Engineering & Computer Science (AREA)
  • Measuring Or Testing Involving Enzymes Or Micro-Organisms (AREA)
  • Investigating Or Analysing Biological Materials (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Analysing Materials By The Use Of Radiation (AREA)
CN201380013105.4A 2012-02-28 2013-02-28 用于诊断阿扎胞苷耐药性的试验 Pending CN104321649A (zh)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
FR1200584A FR2987446B1 (fr) 2012-02-28 2012-02-28 Test diagnostic de la resistance a l'azacitidine
FR12/00584 2012-02-28
PCT/FR2013/000055 WO2013128089A1 (fr) 2012-02-28 2013-02-28 Test diagnostic de la résistance à l'azacitidine

Publications (1)

Publication Number Publication Date
CN104321649A true CN104321649A (zh) 2015-01-28

Family

ID=48083449

Family Applications (1)

Application Number Title Priority Date Filing Date
CN201380013105.4A Pending CN104321649A (zh) 2012-02-28 2013-02-28 用于诊断阿扎胞苷耐药性的试验

Country Status (11)

Country Link
US (1) US20150094217A1 (https=)
EP (1) EP2820417A1 (https=)
JP (1) JP6273552B2 (https=)
CN (1) CN104321649A (https=)
AU (1) AU2013224832A1 (https=)
BR (1) BR112014021173A2 (https=)
CA (1) CA2865684A1 (https=)
FR (1) FR2987446B1 (https=)
IL (1) IL234332A0 (https=)
IN (1) IN2014MN01795A (https=)
WO (1) WO2013128089A1 (https=)

Cited By (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CN114874987A (zh) * 2022-03-01 2022-08-09 洛阳市中心医院（郑州大学附属洛阳中心医院） 一种骨髓异常增生综合征耐药细胞模型及其构建方法和用途

Families Citing this family (3)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
ES2638400T3 (es) * 2014-03-27 2017-10-20 Palacky University, Olomouc Método de predicción de la respuesta tumoral a inhibidores de la metilación del ADN y regímenes terapéuticos alternativos para superar la resistencia
FR3048698B1 (fr) 2016-03-11 2021-03-05 Univ Claude Bernard Lyon Inhibiteurs de l'interaction bcl2 l10 / recepteur ip3
WO2019077080A1 (en) * 2017-10-19 2019-04-25 Universite Claude Bernard Lyon 1 ASSESSING THE RISK OF METASTATIC RECHUTE IN PATIENTS WITH BREAST CANCER

Citations (5)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2005100606A2 (en) * 2004-04-09 2005-10-27 Genomic Health, Inc. Gene expression markers for predicting response to chemotherapy
EP1715041A1 (en) * 2004-02-13 2006-10-25 BML, Inc. Method of detecting cancer cell acquiring drug-resistance
CN101632643A (zh) * 2009-08-18 2010-01-27 杭州咸达医药科技有限公司 阿扎胞苷冻干粉针制剂及其制备方法
JP2010162031A (ja) * 2010-02-22 2010-07-29 Joji Inasawa カンプトテシン類の制癌剤に対する薬剤耐性を獲得した癌細胞の検出方法
WO2011147976A1 (en) * 2010-05-27 2011-12-01 INSERM (Institut National de la Santé et de la Recherche Médicale) Methods for assessing endometrium receptivity of a patient

Family Cites Families (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US20100099109A1 (en) * 2008-10-17 2010-04-22 Nodality, Inc., A Delaware Corporation Methods for Analyzing Drug Response

Patent Citations (5)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
EP1715041A1 (en) * 2004-02-13 2006-10-25 BML, Inc. Method of detecting cancer cell acquiring drug-resistance
WO2005100606A2 (en) * 2004-04-09 2005-10-27 Genomic Health, Inc. Gene expression markers for predicting response to chemotherapy
CN101632643A (zh) * 2009-08-18 2010-01-27 杭州咸达医药科技有限公司 阿扎胞苷冻干粉针制剂及其制备方法
JP2010162031A (ja) * 2010-02-22 2010-07-29 Joji Inasawa カンプトテシン類の制癌剤に対する薬剤耐性を獲得した癌細胞の検出方法
WO2011147976A1 (en) * 2010-05-27 2011-12-01 INSERM (Institut National de la Santé et de la Recherche Médicale) Methods for assessing endometrium receptivity of a patient

Non-Patent Citations (3)

* Cited by examiner, † Cited by third party
Title
IMENE BOUMELA ET AL: "involvement of BCL2 family members in the regulation of human oocyte and early embryo survival and death:gen expression and beyond", 《REPRODDUCTION》 *
SE-JIN YOON ER AL: "Role of bcl2-like 10(Bcl2l10) in regulating mouse oocyte maturation", 《BIOLOGY OF REPRODUCTION》 *
崔晶等: "阿扎胞苷治疗骨髓增生异常综合征转急性白血病1例并文献复习", 《临床血液学杂志》 *

Cited By (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CN114874987A (zh) * 2022-03-01 2022-08-09 洛阳市中心医院（郑州大学附属洛阳中心医院） 一种骨髓异常增生综合征耐药细胞模型及其构建方法和用途

Also Published As

Publication number Publication date
IL234332A0 (en) 2014-10-30
CA2865684A1 (fr) 2013-09-06
EP2820417A1 (fr) 2015-01-07
FR2987446B1 (fr) 2016-01-01
FR2987446A1 (fr) 2013-08-30
WO2013128089A1 (fr) 2013-09-06
BR112014021173A2 (pt) 2017-08-22
AU2013224832A1 (en) 2014-10-16
JP2015513369A (ja) 2015-05-11
IN2014MN01795A (https=) 2015-07-03
JP6273552B2 (ja) 2018-02-07
AU2013224832A8 (en) 2014-11-13
US20150094217A1 (en) 2015-04-02

Similar Documents

Publication Publication Date Title
US10697967B2 (en) Methods for predicting response of triple-negative breast cancer to therapy
EP2694972B1 (en) Methods for predicting and improving the survival of gastric cancer patients
CN103384828A (zh) 使用基于抗体的阵列进行恶性癌症疗法的药物选择
JP5224309B2 (ja) 卵巣明細胞腺癌に特異的に発現しているタンパク質とその応用
Kulshrestha et al. Selective inhibition of tumor cell associated Vacuolar-ATPase ‘a2’isoform overcomes cisplatin resistance in ovarian cancer cells
Radhakrishnan et al. Inhibition of rapamycin-induced AKT activation elicits differential antitumor response in head and neck cancers
CN104321649A (zh) 用于诊断阿扎胞苷耐药性的试验
CN106132435B (zh) 筛选通过促进rip3表达增强抗癌药物的敏感性的抗癌辅剂的方法和试剂盒
Su et al. Comparison of biomarker expression between proximal and distal colorectal adenomas: The Tennessee–Indiana Adenoma Recurrence Study
CN102099493A (zh) 用于预测对抗癌疗法的反应性的组合方法
US10316319B2 (en) Composition for diagnosis of liver metastasis of colorectal cancer and the use thereof
KR102941329B1 (ko) 간암 진단을 위한 바이오마커 조성물
US20100266503A1 (en) Breast Cancer Methods, Medicaments and Agents
JP6478417B2 (ja) 大腸癌患者の生存を予測及び改善するための方法
JP2009516167A (ja) 癌処置における予測マーカーとしてのｐ６６−ｓｈｃ
Class et al. Patent application title: PROGNOSTIC AND/OR PREDICTIVE BIOMARKERS AND BIOLOGICAL APPLICATIONS THEREOF Inventors: Lorenzo Galluzzi (Paris, FR) Annick Harel-Bellan (Paris, FR) Guido Kroemer (Paris, FR) Ken Olaussen (Paris, FR) Jean-Charles Soria (Igny, FR) Assignees: INSTITUT GUSTAVE ROUSSY
HK1178602B (en) Methods for predicting response of triple-negative breast cancer to therapy

Legal Events

Date Code Title Description
C06 Publication
PB01 Publication
C10 Entry into substantive examination
SE01 Entry into force of request for substantive examination
C02 Deemed withdrawal of patent application after publication (patent law 2001)
WD01 Invention patent application deemed withdrawn after publication

Application publication date: 20150128